FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus; Guidance for Industry” was released on October 2, 2019 and recommends that CTS modify our current HCV reflex testing algorithm to support these best practices. The new algorithm will take effect on April 20, 2020.
Check out the Communication page for the complete details by clicking the link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...